Hyperinfection in Strongyloides stercoralis
Hyperinfection is a life-threatening condition characterized by massive, uncontrolled multiplication of Strongyloides stercoralis larvae throughout the body, occurring primarily in immunocompromised patients, with mortality rates approaching 87-90%. 1, 2
Pathophysiology
Hyperinfection represents an exponential increase in parasitic burden beyond the gastrointestinal tract and lungs 3. Unlike uncomplicated strongyloidiasis where autoinfection maintains chronic low-level infection, hyperinfection occurs when the immune system fails to control larval replication. This leads to:
- Massive larval migration through multiple organ systems
- Tissue invasion and direct organ damage
- Translocation of enteric bacteria causing polymicrobial bacteremia 3, 4
Clinical Manifestations
Respiratory symptoms are prominent and include:
- Cough and breathlessness 5
- Alveolar hemorrhages 4
- Respiratory failure requiring mechanical ventilation (68% of cases) 6
Gastrointestinal symptoms include:
- Diarrhea and intestinal bleeding 4
- Abdominal pain
Systemic manifestations:
Critical Risk Factors
The most important risk factor is corticosteroid therapy (present in 83.5% of ICU cases) 6. Other immunosuppressive conditions include:
- Solid organ transplantation 3
- HTLV-1 infection 1
- Malignancy and chemotherapy 2
- COVID-19 patients receiving steroids 1, 3
- Hypogammaglobulinemia 1
Diagnostic Approach
Critical diagnostic pitfall: Serology may be negative in hyperinfection 5.
Send both stool AND sputum microscopy when hyperinfection is suspected 5. Larvae can be visualized in:
Eosinophilia is often absent in hyperinfection (only 34% of cases) 6, which paradoxically predicts better outcomes as its absence correlates with shock development 6.
Treatment
Prolonged ivermectin treatment is required—seek specialist advice immediately 5. Standard dosing is insufficient for hyperinfection.
For immunocompromised patients with uncomplicated strongyloidiasis, the guideline recommends: Ivermectin 200 µg/kg on days 1,2,15, and 16 5. However, hyperinfection requires even more intensive regimens determined by specialists.
Prognostic Factors
Independent predictors of ICU mortality:
Concomitant bacterial infection independently predicts shock development (OR 4.68) 6, while paradoxically, hypereosinophilia is protective against shock (OR 0.21) 6.
Prevention Strategy
Screen all at-risk patients BEFORE initiating immunosuppression 3, 7. This includes:
- Patients from endemic areas (tropics/subtropics)
- Anyone starting corticosteroids or other immunosuppressants
- Transplant candidates
When timely testing is unavailable, empirical ivermectin treatment should be administered 7 rather than risk fatal hyperinfection. The 2025 UK guidelines emphasize this proactive approach given the catastrophic mortality of established disease 5.
Critical Caveat
Never use corticosteroids empirically in patients with potential strongyloidiasis 5. Steroids can precipitate hyperinfection in chronic carriers, including those with decades-long latent infection 7. This is particularly relevant for COVID-19 management where steroids are commonly used 1, 3.